

# Fast Facts

DECEMBER COVID-19 SPECIAL EDITION 2020

News for Providers from HealthPartners Professional Services and Hospital Network Management

## Vaccine and treatment Frequently asked questions

### Coronavirus (COVID-19) information

UPDATED: 12/10/2020

Please review the following coverage updates to support your efforts to contain and minimize the impact of the coronavirus (COVID-19). We encourage providers to access our website regularly for updates as more information becomes available.

#### WHAT IS HEALTHPARTNERS APPROACH FOR REMDESIVIR BILLING?

- Remdesivir is covered in the inpatient setting and included in the DRG payment for inpatient stays.
- Remdesivir is also covered and paid when administered in the outpatient setting. Codes C9399 (outpatient setting) and J3490 (clinic/home setting) can be used to bill for Remdesivir when not delivered in the inpatient setting, with the appropriate administration code.
- Administration in the outpatient setting, clinic, or home should be limited to situations when hospital admission is not available.
- Providers are expected to follow FDA labeling for patient selection. Providers must ensure the availability and use of patient monitoring and care capabilities necessary to manage and treat all potential side effects and complications associated with remdesivir infusion.

#### WHAT IS HEALTHPARTNERS APPROACH FOR MONOCLONAL ANTIBODY THERAPY (BAMLANIVIMAB) BILLING?

- Monoclonal antibody therapy is currently distributed according to a set process determined by the federal government. [CMS outlines details in this document.](#)  
*(path: cms.gov/files/document/covid-medicare-monoclonal-antibody-infusion-program-instruction.pdf)*
- Similar to CMS, HealthPartners will not pay for any monoclonal antibody therapy that a provider receives for free. If providers begin to purchase monoclonal antibody therapy, HealthPartners will determine a reimbursement amount, again following Medicare's lead.
- Monoclonal antibody therapy is billed using code Q0239.
- Administration for monoclonal antibody therapy is billed using code M0239, with reimbursement of \$309.60.

## WHAT IS HEALTHPARTNERS APPROACH FOR MONOCLONAL ANTIBODY TREATMENT COCKTAIL (CASIRIVIMAB/IMDEVIMAB) BILLING?

- On November 21, 2020, Regeneron received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the investigational monoclonal antibody treatment cocktail Casirivimab/Imdevimab. [Click HERE for Casirivimab/Imdevimab information](#) (path: [phe.gov/emergency/events/COVID19/investigation-MCM/cas\\_imd/Pages/default.aspx](https://www.phe.gov/emergency/events/COVID19/investigation-MCM/cas_imd/Pages/default.aspx))
- Based on current information, the monoclonal treatment cocktail casirivimab/imdevimab is being distributed by federal and state governments. [Click HERE for more HHS information](#) (path: <https://www.hhs.gov/about/news/2020/11/23/hhs-allocates-regeneron-therapeutic-treat-patients-mild-moderate-covid-19.html>)
- HealthPartners will not pay for any monoclonal antibody treatment cocktail that a provider receives for free. If providers begin to purchase monoclonal antibody treatment cocktail, HealthPartners will determine a reimbursement amount, again following Medicare's lead.
- Administration for monoclonal antibody cocktail should be billed using the most appropriate infusion administration code until a specific administration codes is issued.

## WHAT IS HEALTHPARTNERS APPROACH FOR COVID-19 VACCINE BILLING?

- Several COVID-19 vaccines have been submitted for FDA approval.
- Codes for administration and the vaccines will be issued with separate codes and vaccines for each vaccination approved. [Click HERE for more detailed information on COVID-19 vaccination coding](#) (click on each topic in the Table of Contents to see more information). (path: <https://www.cms.gov/covidvax-provider>)
- It is anticipated that the initial doses of vaccinations will be federally purchased and distributed. Any federally purchased vaccinations should not be billed and will not be reimbursed. Reimbursement amounts for the vaccines will be updated at a later date. Vaccination administration codes will be reimbursed with no member cost share.
- HealthPartners Medicare members vaccination administration reimbursement:
  - **Medicare:** All Medicare Advantage and Medicare Cost members will receive COVID-19 coverage and reimbursement though Medicare Fee-For-Service. These services should be billed directly to Medicare FFS, not to HealthPartners. This approach will be in place for 2020 and 2021. [More Medicare information is available HERE](#) (path: [cms.gov/medicare/covid-19/medicare-billing-covid-19-vaccine-shot-administration](https://www.cms.gov/medicare/covid-19/medicare-billing-covid-19-vaccine-shot-administration) and [HERE](#) (path: [cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-mono-clonal-antibodies](https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-mono-clonal-antibodies)).
  - **Medicaid:** We anticipate vaccination administration to be billed to each MCO, more details will be provided as they are released.
  - **Commercial:** Vaccination administration should be billed to HealthPartners using the same codes as Medicare. HealthPartners will reimburse \$28.39 for single dose vaccines. For 2-dose vaccinations, HealthPartners will reimburse \$16.94 for the first dose and \$28.39 for the second dose.

If you have questions regarding the content of this newsletter, please contact the person indicated in the article or call your HealthPartners Service Specialist. If you don't have his/her phone number, please call **952-883-5589** or toll-free at **888-638-6648**. This newsletter is available online at [healthpartners.com/fastfacts](https://healthpartners.com/fastfacts).

**Fast Facts Editors:** Mary Jones and David Ohmann